GHK

Tissue Repair & HealingResearch Only

Solid preclinical research foundation with demonstrated biological effects, but human clinical data remains surprisingly sparse for such a well-studied peptide. The 30-study evidence base is largely built on laboratory and animal work.

Predominantly studied by cosmetic dermatology researchers and tissue engineering labs focused on wound healing applications.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

30 total, 6 human

What is GHK?

This three-amino acid peptide occurs naturally in human plasma and serves as the foundation for copper-binding variants like GHK-Cu. Researchers primarily investigate its role in accelerating tissue repair processes and supporting healthy aging mechanisms. Dermatology and regenerative medicine labs frequently examine GHK for its ability to influence how cells rebuild damaged tissue.

GHK works by binding to specific cellular receptors and influencing the expression of genes responsible for building new tissue components like collagen and elastin. Think of it as a molecular foreman that tells cells when to start construction projects—it can upregulate genes that build healthy tissue while downregulating those associated with inflammation and scarring. The peptide also appears to reset certain cellular programs back to more youthful states.

What the Research Shows

While 30 studies provide a substantial research foundation, only 6 human studies limits clinical applicability, with most evidence derived from cell culture and animal models.

A total of 30 studies on GHK peptide have been identified, including 11 human studies and 1 randomized controlled trial. The evidence base demonstrates GHK's effects on collagen and glycosaminoglycan synthesis, gene regulation for skin regeneration, anti-inflammatory and anti-cancer properties, and rescue of smoking-induced muscle dysfunction in preclinical models, though the limited number of human trials constrains definitive clinical conclusions.